| Entry |
|
|---|
| Name |
Cytarabine;
Cytosine arabinoside;
Cytosine-1-beta-D-arabinofuranoside;
Ara-C
|
|---|
| Formula |
C9H13N3O5
|
|---|
| Exact mass |
243.0855
|
|---|
| Mol weight |
243.22
|
|---|
| Structure |
|
|---|
| Remark |
|
|---|
| Brite |
Glycosides [BR:br08021]
N-glycosides
C02961 Cytarabine
Prodrugs [br08324.html]
C02961
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BC Pyrimidine analogues
L01BC01 Cytarabine
D00168 Cytarabine (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Cytarabine
D00168 Cytarabine (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4224 Cytosines
D00168 Cytarabine (JP18/USP/INN)
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00686 Cytarabine
D00168 Cytarabine
Drug classes [BR:br08332]
Antineoplastic
DG02018 Antimetabolite
D00168 Cytarabine
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00168 Cytarabine
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00168
Prodrugs [br08324.html]
D00168
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 17
1 C1y C 23.7300 -16.9400
2 N4y N 25.0600 -16.5200
3 O2x O 22.6100 -16.1700
4 C1y C 23.3100 -18.2700
5 C8y C 26.2500 -17.2200
6 C8x C 25.0600 -15.1200
7 C1y C 21.4900 -16.9400
8 C1y C 21.9100 -18.2700
9 O1a O 24.0800 -19.4600
10 N5x N 27.5100 -16.5200
11 O5x O 26.2500 -18.6200
12 C8x C 26.2500 -14.4200
13 C1b C 20.0900 -16.5200
14 O1a O 21.0700 -19.4600
15 C8y C 27.5100 -15.1200
16 O1a O 19.1100 -17.5000
17 N1a N 28.7000 -14.4200
BOND 18
1 1 2 1 #Up
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 4 8 1
8 4 9 1 #Up
9 5 10 1
10 5 11 2
11 6 12 2
12 7 13 1 #Up
13 8 14 1 #Down
14 10 15 2
15 13 16 1
16 15 17 1
17 7 8 1
18 12 15 1
|
|---|
